Home » King Pharmaceuticals Focusing on Licensing and Acquiring Products
King Pharmaceuticals Focusing on Licensing and Acquiring Products
April 13, 2005
Licensing and acquiring products will be the focus for King Pharmaceuticals Incorporated of Bristol. King president Brian Markison says the company is being transformed following a botched $4 billion merger with Mylan Laboratories Incorporated earlier this year. King, a generic and brand-name drug company, has seen its shares lose 40 percent of their value the last four months.
Big News Network (http://feeds.bignewsnetwork.com/redir.php?jid=2b5706aeaa2cb769&cat=6dcd932030878143)
(http://feeds.bignewsnetwork.com/redir.php?jid=2b5706aeaa2cb769&cat=6dcd932030878143)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct